Alios BioPharma, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03439488
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
π²π©Republican Clinical Hospital, Chisnau, Moldova, Republic of
π³πΏAuckland Clinical Services, Auckland, New Zealand
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03411421
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03285620
- Locations
- π³πΏ
Auckland Clinical Studies, Ltd., Auckland, New Zealand
A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03253471
- Locations
- π§πͺ
SGS Life Sciences, Antwerp, Belgium
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects
Phase 2
Withdrawn
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Registration Number
- NCT03125213
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
Phase 1
Terminated
- Conditions
- Viral Hepatitis BChronic Hepatitis BHepatitis B
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03032536
- Locations
- π³πΏ
Auckland Clinical Studies, Auckland, New Zealand
π³πΏChristchurch Clinical Studies Trust, Christchurch, New Zealand
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
Phase 1
Completed
- Conditions
- Influenza in Humans
- Interventions
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT02888327
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
A Study to Assess the PK of AL-794 Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: AL-794 suspensionDrug: AL-794 tablet
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02877160
- Locations
- π¬π§
Hammersmith Medicines Research Ltd (HMR), London, United Kingdom
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02673476
- Locations
- πΈπ¬
Raffles Hospital, Singapore, Singapore
πΊπΈSt Lucie Medical Center, Port Saint Lucie, Florida, United States
πΊπΈThe Research Center, Inc., Hialeah, Florida, United States
A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02588521
- Locations
- π¬π§
Hammersmith Medicines Research Ltd (HMR), London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath